Skip to main content
. 2021 Dec;191(12):2231–2244. doi: 10.1016/j.ajpath.2021.08.012

Figure 2.

Figure 2

Pharmacologic inhibition of B cell–activating factor (BAFF) attenuates abdominal aortic aneurysm (AAA) growth. A and B: In the prevention strategy, wild-type mice were intravenously injected with 1 mg/kg or 2 mg/kg of anti-BAFF antibody (Ab), 2 mg/kg of mBaffR-mFc (murine BAFF receptor 3 ecto-domain fused to murine IgG1 Fc fragment that blocks binding of BAFF to BAFF receptor 3), or a control Ab once in 14 days. After 14 days of the Ab injection, AAA was induced via the topical elastase model. Aorta diameter (in millimeters) and increase in aorta diameter (%) compared with a proximal elastase untreated abdominal aortic segment was determined after 14 days of AAA induction. C: In the intervention strategy, AAA was induced in three groups of wild-type mice via the topical elastase model. Seven days after the induction, the mice were injected intravenously with 2 mg/kg control Ab, anti-BAFF, or mBaffR-mFc. Seven days after the Ab injection, aorta diameter (in millimeters) and increase in aorta diameter (%) were determined. Data are expressed as means ± SEMs. n = 6 to 7 (A and B, 1 mg/kg of anti-BAFF Ab); n = 5 to 6 (A and B, 2 mg/kg of anti-BAFF Ab); n = 8 (A and B, 2 mg/kg of mBaffR-mFc); n = 6 per group (C). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 (one-way analysis of variance followed by a parametric unpaired t-test).